PELTHOS THERAPEUTICS INC
PTHSNYSE AMERICAN🏆 #4193 by market capEarnings Nov 12US Equity
$16.12▲ $1.52 (+10.38%)
Latest quoteTrack PTHS
Get earnings, price moves & breaking news on Telegram
24h▲ 10.4%
7d▼ 18.4%
14d▼ 21.4%
30d▼ 26.2%
ytd▼ 45.5%
1y▼ 52.6%
🏦Market Cap
$62M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
78.6%
High
💵FCF Margin
—
⚖️P/S Ratio
1.3x
Cheap
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $14.58 – $16.11
- 52-Week Range
- $14.44 – $37.50
- Volume (shares)
- 1,074
- Avg Volume (shares)
- —
- Shares Outstanding
- 3.8M
- Next Earnings
- 2026-11-12
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 1.3x
- EPS (TTM)
- $-21.82
- Dividend Yield
- —
- Dilution (1yr)
- +429.3%
PELTHOS THERAPEUTICS INC
PTHSFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$17M▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$32M▲ +328.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$23M▲ +291.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
3.2M▲ +429.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$17M▼ −$15M YoY
StockOtter · stockotter.spaceAbout PELTHOS THERAPEUTICS INC
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💎Quality★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
13 analysts
Strong Buy3
Buy9
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.